Research from industry analyst GlobalData shows that USA-based cardiorenal specialist Ardelyx (Nasdaq: ARDX) has the potential to make significant inroads with its candidate tenapanor.
Previously out-licensed to AstraZeneca (LSE: AZN), tenapanor is an inhibitor of intestinal sodium/hydrogen exchanger 3, which reduces phosphate absorption.
Since 2019 the drug has been approved in the USA for irritable bowel syndrome (IBS), and is marketed as Ibsrela in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze